Login / Signup

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Tomoaki SonodaYukihiro UmedaYoshiki DemuraToshihiko TadaKoki NakashimaMasaki AnzaiMakiko YamaguchiAkikazu ShimadaMasahiro OhiChisato HonjoYuko WasedaMasaya AkaiTamotsu Ishizuka
Published in: Cancer medicine (2023)
Nab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • clinical trial
  • combination therapy
  • open label
  • double blind
  • cross sectional
  • tyrosine kinase
  • phase ii
  • mesenchymal stem cells
  • stem cells